Clinical Trials/NCT01311050

NCT01311050

Unknown

Not Applicable

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

King Faisal Specialist Hospital & Research Center1 site in 1 country46 target enrollmentJanuary 2009

ConditionsMetastatic Colorectal Cancer

DrugsCapecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Metastatic Colorectal Cancer
Sponsor: King Faisal Specialist Hospital & Research Center
Enrollment: 46
Locations: 1
Last Updated: 14 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Detailed Description

A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

Registry

clinicaltrials.gov

Start Date

January 2009

End Date

TBD

Last Updated

14 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

King Faisal Specialist Hospital & Research Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with diagnosed Metastatic Colorectal Cancer

Exclusion Criteria

•Patients with diagnosis other than Metastatic Colorectal Cancer

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials

Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCancer of the GallbladderCancer of the Biliary Tract

NCT00338988M.D. Anderson Cancer Center44

Phase I trial of capecitabine, oxaliplatin and irinotecan combination chemotherapy (XELOXIRI) for advanced gastric cancerAdvanced gastric cancer

JPRN-UMIN000022861Kyushu University18

Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal CancerColorectal Cancer

NCT00220116Royal Marsden NHS Foundation Trust172

CO07204-Phase I/II of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary CarcinomaPancreatic NeoplasmsBile Duct Neoplasms

NCT00634751University of Wisconsin, Madison48

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular CancerLiver CancerHepatocellular Cancer

NCT03026803City of Hope Medical Center4